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DNA methylation in the promoter regions of genes is a prom-
inent epigenetic gene silencing mechanism associated with resis-
tance to endocrine therapy in patients with recurrent breast
cancer. We have employed a microarray-based technology to
investigate the promoter DNA methylation status of 117 candi-
date genes in tumors of breast cancer patients who received
tamoxifen as first-line endocrine treatment for recurrent breast
cancer. Of the genes analyzed, phosphoserine aminotransferase
(PSA-T1) emerged as the strongest marker to predict progres-
sion-free survival. Among the 117 candidate genes, DNA-methyl-
ation markers associated with breast cancer patient outcome
after adjuvant endocrine therapy were also identified and vali-
dated in independent groups of patients. DNA-methylation status
of PITX2 showed the strongest correlation with disease recur-
rence. These results provide validated high-level evidence that
DNA-methylation status allows clinically relevant risk assess-
ment in tamoxifen-treated breast cancer, both in the adjuvant
and palliative setting.
doi:10.1016/j.ejcsup.2006.04.024
S24. MOLECULAR PATHOGENESIS OF PAPILLOMA VIRUS
ASSOCIATED CANCERS
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of Pathology, University of Heidelberg, Germany.
A number of human cancers are caused by persistent infections
with high risk human papilloma viruses (HR-HPV), among them
about 100% of cervical cancers, many anogenital cancers, some
head and neck cancers, and a subset of skin cancers. HPVs
infect basal epithelial cells via microlesions and usually replicate
in differentiated superficial epithelial cells. Two HPV oncogenes,
E6 and E7, interfere with the hosts cell cycle and apoptosis reg-
ulation. Most importantly, E7 disrupts the binding of pRb and
E2F and induces continuous cell cycle activation. E6 triggers deg-
radation of p53 and thus abrogates apopotosis. Local immune
defense mechanisms lead to spontaneous clearance of HPV
infections in the majority of cases. In few infections, however,
deregulated expression of E6 and E7 in basal epithelial cells
induces major chromosomal instability and can initiate epithe-
lial transformation. Several characteristic changes have been
identified in epithelial cells transformed by HPV: Strong
p16INK4a expression was found in medium to high grade pre-
malignant lesions as well as in cervical cancer indicating the
functional inactivation of pRb. Proliferation associated markers
like ki67, telomerase, MCM5 and CDC6 are expressed at various
levels in premalignant lesions and invasive cancer. In advanced
lesions, high levels of chromosomal imbalances can be
observed, a very specific alteration is the gain of 3q. Integration
of HPV DNA into the host cell genome specifically indicates
advanced lesions with a high probability of progression and is
frequently found in cervical cancer. Several biomarkers, espe-
cially the detection of HR-HPV DNA and p16INK4a protein, are
currently being evaluated in order to improve existing cervical
cancer screening procedures.
doi:10.1016/j.ejcsup.2006.04.025
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Andreas Mackensen. Department of Hematology/Oncology,
University of Regensburg, Germany.
Vaccination against cancer has had a variable history, with claims
of success often fading into disappointment. The reasons for this
include poor vaccine design, inadequate understanding of the
nature of the immune response, and a lack of objective measures
to evaluate performance. The characterization of tumor-associ-
ated antigens (TAAs) recognized by human T lymphocytes in a
MHC-restricted fashion has opened new possibilities for specific
vaccine approaches to the treatment of human cancers. Recent
findings include vaccine formulation, relevant knowledge con-
cerning mechanisms of induction of effective immunity from pre-
clinical models, and translation into clinical trials. We now have
novel vaccine strategies to activate specific attack on tumor cells
and we understand more about activation and regulation of
immunity against cancer (co-stimulation versus co-inhibition,
regulatory T cells). We also have modern assays using surrogate
markers (MHC multimer analysis, IFN-c Elispot assay) to correlate
with clinical effects. Although early clinical vaccine trials based
on synthetic peptides, proteins, ‘naked’ DNA, tumor-RNA, den-
dritic cells, and recombinant vaccinia viruses indicate that vac-
cines can induce immune responses and tumor regression in
some cancer patients, careful study design and use of standard-
ized clinical and immunological criteria are needed. Basic princi-
ples of tumor vaccination and clinical trials will be discussed.
doi:10.1016/j.ejcsup.2006.04.026
S26. TARGETING MUC1 WITH LIPOSOMAL BLP25
Martin H. Falk, Karl-Josef Kallen. Merck KGaA, Darmstadt,
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MUC1 is a mucin glycoprotein expressed by both normal cells and
a wide variety of epithelial carcinomas. Mucins expressed by can-
cer cells have abnormal glycosylation that results in shorter and
simpler carbohydrate chains as well as exposure of normally hid-
den (cryptic) epitopes on the protein backbone. These changes
result in unique antigenicity of cancer cell mucins relative to their
normal cell counterparts and make MUC1 an ideal candidate
antigen for immunotherapy.
L-BLP25 vaccine is an investigational therapeutic cancer vac-
cine being studied for the treatment of epithelial carcinomas.
L-BLP25 vaccine incorporates a synthetic lipopeptide sequence
identical to a portion of the protein backbone of MUC1. The vac-
cine is a liposomal formulation that consists of the synthetic
MUC1 lipopeptide, an immunoadjuvant [monophosphoryl lipid
A (MPL)], and three lipids: cholesterol, dimyristoyl phosphatidyl-
glycerol (DMPG) and dipalmitoyl phosphatidylcholine (DPPC).
The BLP25 lipopeptide provides the antigenic specificity for a T-
cell immune response, while the adjuvant serves to TLR4 to acti-
vate APCs. The liposomal delivery system is thought to ensure
delivery of peptide antigen and adjuvant to the exact same cell
as well as facilitate access to the intracellular antigen presenting
machinery of a cell.
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